AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
Last Of Three Phase III Readouts Also Positive
Executive Summary
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.
You may also be interested in...
Keeping Track: Psoriasis Gets New Topical In Arcutis’ Zoryve; Cidara Submits IV Antifungal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.
FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands
Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.